Fig. 7

PSPM-NPs inhibit the progression and metastasis of RCC in vivo. A Representative bioluminescence images of subcutaneous xenograft model with intravenous injection of PBS, Sunitinib, PSPM-NPs and PSPM-NPs + Sunitinib. B, C Tumor weight (B) and volume (C) in the subcutaneous xenograft model. D Representative IHC images of subcutaneous xenograft model. E IHC scores of Ki67 and UPF1 in the subcutaneous xenograft model. F Representative bioluminescence images of tail vein metastasis model with intravenous injection of PBS, Sunitinib, PSPM-NPs and PSPM-NPs + Sunitinib. G-I Lumineacence (G) and lung matastases (H, I) in the tail vein metastasis model. J Tumor weight in the tail vein metastasis model. (*p < 0.05, **p < 0.01, ***p < 0.001). Abbreviations: PSPM-NPs, Plasmid-SLERCC@PDA@MUC12 nanoparticles; RCC, Renal cell carcinoma